Medirom Common Stock Total Equity from 2010 to 2024
| MRM Stock | USD 3.02 0.22 6.79% |
Common Stock Total Equity | First Reported 2010-12-31 | Previous Quarter 1.4 B | Current Value 740.5 M | Quarterly Volatility 440.1 M |
Check Medirom Healthcare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medirom Healthcare's main balance sheet or income statement drivers, such as Interest Income of 2 M, Depreciation And Amortization of 135.8 M or Interest Expense of 38.7 M, as well as many indicators such as Price To Sales Ratio of 0.58, Dividend Yield of 0.0 or PTB Ratio of 20.74. Medirom financial statements analysis is a perfect complement when working with Medirom Healthcare Valuation or Volatility modules.
Medirom | Common Stock Total Equity |
Latest Medirom Healthcare's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Medirom Healthcare Technologies over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Medirom Healthcare's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Medirom Healthcare's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Medirom Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 562,405,914 | |
| Geometric Mean | 429,574,726 | |
| Coefficient Of Variation | 78.25 | |
| Mean Deviation | 380,767,097 | |
| Median | 245,100,000 | |
| Standard Deviation | 440,076,559 | |
| Sample Variance | 193667.4T | |
| Range | 1.1B | |
| R-Value | 0.80 | |
| Mean Square Error | 75028.1T | |
| R-Squared | 0.64 | |
| Significance | 0.0003 | |
| Slope | 78,739,568 | |
| Total Sum of Squares | 2711343.3T |
Medirom Common Stock Total Equity History
About Medirom Healthcare Financial Statements
Medirom Healthcare investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how Medirom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 1.4 B | 740.5 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Medirom Stock
When determining whether Medirom Healthcare is a strong investment it is important to analyze Medirom Healthcare's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Medirom Healthcare's future performance. For an informed investment choice regarding Medirom Stock, refer to the following important reports:Check out the analysis of Medirom Healthcare Correlation against competitors. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share 0.15 | Revenue Per Share 1.4 K | Quarterly Revenue Growth (0.06) | Return On Assets (0.04) |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.